PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02462707
Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
- Conditions
- Hemophilia A
- Interventions
- Drug: Intravenous infusions of Xyntha
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT02461992
- Locations
- 🇨🇳
Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing, China
🇨🇳Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing, China
Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Biological: bococizumab PFP
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 470
- Registration Number
- NCT02458209
- Locations
- 🇺🇸
Broward Research Group, Hollywood, Florida, United States
🇺🇸Miami Research Associates, LLC, South Miami, Florida, United States
🇺🇸MRA Clinical Research, LLC, South Miami, Florida, United States
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
- Conditions
- Hyperlipidemia
- Interventions
- Biological: Bococizumab 150mgBiological: Bococizumab 75mgBiological: Bococizumab 150mg placeboBiological: Bococizumab 75mg placebo
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 299
- Registration Number
- NCT02458287
- Locations
- 🇺🇸
Omega Clinical Research Center, Metairie, Louisiana, United States
🇺🇸National Research Institute, Los Angeles, California, United States
🇺🇸A & R Research Group LLC, Pembroke Pines, Florida, United States
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
- Conditions
- Chemotherapy-Induced Neutropenia
- Interventions
- Biological: Nivestim®
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1160
- Registration Number
- NCT02454530
- Locations
- 🇫🇷
Centre Hospitalier du Pays d'Aix Service d'Hématologie - Oncologie, Aix En Provence, France
🇫🇷CH d'Armentières Service Oncologie, Armentieres, France
🇫🇷Clinique du Dr Maymard Service d'Oncologie, Bastia, France
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02444793
- Locations
- 🇺🇸
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects
- Conditions
- Healthy Adult Subjects and Healthy Elderly Subjects
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 92
- Registration Number
- NCT02440100
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02430545
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis
- Conditions
- Late-onset Sepsis
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT02424734
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇭🇺Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Gyermek-, Koraszulott es Csecsemoosztaly, Budapest, Hungary
🇭🇺Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet, Gyermekinfektologiai Osztaly, Budapest, Hungary
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: PF-06412562 3mg BIDDrug: PF-06412562 9mg BIDDrug: PF-06412562 45mg BIDOther: Placebo
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 103
- Registration Number
- NCT02418819
- Locations
- 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Arcadia MRI & Imaging Center, Arcadia, California, United States